ABSTRACT:
Thiazolidine is become an important ring in the development various antagonist against different diseases such as diabetes, cancer, inflammation, microbial infection etc. Thiazolidine derivatives showed improved pharmacological activity in different pathophysiological conditions than its standard drug. Thiazolidine2,4-dione, 1, 3 thiazolidines, 2, 4 dione,4-oxo thiazolidine contains basic thiazolidine skeleton. The present science migrates to the development of drugs on the basis of structure-based drug design in the presence of protein structure. The difference between the designed drug and their synthesis can be minimized by showing the ligand protein interaction. The present study includes the thiazolidine derivatives and their pharmacological activities in the treatment of various diseases.
Cite this article:
Pawan Bajpai, Shelesh Jain, Ankur Choubey. Thiazolidine, A Versatile ring in the treatment of various Diseases: A Systematic Review. Asian J. Research Chem. 2020; 13(4):283-286. doi: 10.5958/0974-4150.2020.00055.3
Cite(Electronic):
Pawan Bajpai, Shelesh Jain, Ankur Choubey. Thiazolidine, A Versatile ring in the treatment of various Diseases: A Systematic Review. Asian J. Research Chem. 2020; 13(4):283-286. doi: 10.5958/0974-4150.2020.00055.3 Available on: https://ajrconline.org/AbstractView.aspx?PID=2020-13-4-9
REFERENCES:
1. M.M. Ip, P.W. Sylvester, L. Schenkel, Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion, Cancer Res, 46 (1986) 1735-1740.
2. T. Fujita, Y. Sugiyama, S. Taketomi, T. Sohda, Y. Kawamatsu, H. Iwatsuka, Z. Suzuoki, Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent, Diabetes, 32 (1983) 804-810.
3. L.F. da Rocha Junior, M.J. Rego, M.B. Cavalcanti, M.C. Pereira, M.G. Pitta, P.S. de Oliveira, S.M. Goncalves, A.L. Duarte, C. de Lima Mdo, R. Pitta Ida, Synthesis of a novel thiazolidinedione and evaluation of its modulatory effect on IFN- gamma , IL-6, IL-17A, and IL-22 production in PBMCs from rheumatoid arthritis patients, Biomed Res Int, 2013 (2013) 926060.
4. A.M. Youssef, M.S. White, E.B. Villanueva, I.M. El-Ashmawy, A. Klegeris, Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents, Bioorg Med Chem, 18 (2010) 2019-2028.
5. U. Albrecht, D. Gordes, E. Schmidt, K. Thurow, M. Lalk, P. Langer, Synthesis and structureactivity relationships of 2-alkylidenethiazolidine-4,5-diones as antibiotic agents, Bioorg Med Chem, 13 (2005) 4402-4407.
6. T. Sohda, Y. Momose, K. Meguro, Y. Kawamatsu, Y. Sugiyama, H. Ikeda, Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy) benzyl]-2,4-thiazolidinediones, Arzneimittelforschung, 40 (1990) 37-42.
7. T.P. Ciaraldi, A. Gilmore, J.M. Olefsky, M. Goldberg, K.A. Heidenreich, In vitro studies on the action of CS-045, a new antidiabetic agent, Metabolism, 39 (1990) 1056-1062.
8. N.D. Oakes, C.J. Kennedy, A.B. Jenkins, D.R. Laybutt, D.J. Chisholm, E.W. Kraegen, A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat, Diabetes, 43 (1994) 1203-1210.
9. J.W. Kim, J.R. Kim, S. Yi, K.H. Shin, H.S. Shin, S.H. Yoon, J.Y. Cho, D.H. Kim,S.G. Shin,I.J. Jang, K.S. Yu, Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind,randomized control study in healthy male Korean subjects, Clin Ther, 33 (2011) 1819-1830.
10. Zheng H, Dong Y, Lin L, Sun B, Liu L, Yuan H, Lou H. Novel benzo[a]quinolizidine analogs induce cancer cell death through paraptosis and apoptosis. J Med Chem. 2016; 59:5063–5076.
11. Singh T, Srivastava, V. K, Saxena, K. K, Goel, S. L, Kumar, A. Arch. Pharm. Chem. Life Sci? 46 (2006) 339.
12. Sayed, M, Mokle, S, Bokhare, M. Mankar, A, Surwase, S Bhusare, S. Vibhute, Y. ARKIVOC II (2006) 187.
13. Gududuru, V, Hurh, H, Dalton, J. T. Miller, D. D. Bioorg.Med.Chem. Lett 14 (2004) 5289.
14. Rahman, V. P. M. Mukhtar, S. Ansari, W. H. Lemiere, G. Eur. J. Med.Chem 40(2005) 173.
15. Ottana, R. Mazzon, E. Dugo, L. Monforte, F. Maccari, R. Sautebin, L. DeLuca, G. Vigorita, M. G. Alcaro, S. Ortuso, F. Caputi, A.P. Cuzzocrea, S. Eur. J. Pharmacol.448 (2002)71.
16. Bhati, S. K. Kumar, A. Eur. J. Med. Chem 43 (2008)2323.
17. Uchoa, F. Silva, T. Lima, M. Galdino, S. Pitta, I. Costa, T. D. J. Pharm. Pharmacol 61 (2009) 339.
18. Amin, K. M. Kamel, M. M. Anwar, M. M. Khedr, M. Syam, Y. N. Eur. J. Med. Chem 45 (2010) 2117.
19. Akula, G. Srinivas, B. Vidyasagar, M. Kandikonda, S. Int. J. Pharm. Tech. Res. 3 (2011) 360.
20. Chen, H. Bai, J. Jiao, L. Guo, Z. Yin, Q. Li, X. Bioorg. Med. Chem 17 (2009) 3980
21. Chen X, Yang L, Zhai SD Chin.Med. J. 125, 23(2012) 4301–6.
22. Cohen, J. S. (2006) Diabetologia. 49(2006) 1454.
23. https://www.drugs.com.